683 Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

683 Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-825,000	Closed	-$19.9M	–	307
2023 Q1	$19.9M	Buy	825,000 +275,000	+50%	+$3.45M	1.48%	20
2022 Q4	$5.81M	Buy	+550,000	New	+$4.44M	0.49%	54
2021 Q4	–	Sell	-198,429	Closed	-$1.27M	–	378
2021 Q3	$1.27M	Sell	198,429 -100,000	-34%	-$643K	0.05%	135
2021 Q2	$2.52M	Sell	298,429 -331,571	-53%	-$2.68M	0.09%	114
2021 Q1	$6.61M	Sell	630,000 -229,314	-27%	-$3.23M	0.35%	62
2020 Q4	$14.6M	Hold	859,314	–	–	0.69%	37
2020 Q3	$11M	Buy	859,314 +259,314	+43%	+$3.28M	0.81%	30
2020 Q2	$8.47M	Buy	+600,000	New	+$7.58M	0.68%	35
2020 Q1	–	Sell	-15,608	Closed	-$233K	–	190
2019 Q4	$233K	Buy	+15,608	New	+$139K	0.03%	93

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

683 Capital Management's PRVB Position: Q2 2023 in Review

683 Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 825,000 shares — an estimated $19.9M sold.

683 Capital Management first reported a position in PRVB in Q4 2019 and held it in 9 quarters. The position peaked at $19.9M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

683 Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 825,000 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $19.9M.
683 Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
683 Capital Management's Provention Bio, Inc. Common Stock position peaked at $19.9M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.